<DOC>
	<DOC>NCT00726323</DOC>
	<brief_summary>This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.</brief_summary>
	<brief_title>A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<criteria>Histologically confirmed diagnosis of PRC with metastatic disease or bilateral multifocal renal tumors localized to kidneys. Measurable disease, ECOG performance status of &lt;/= 2. Adequate bone marrow reserve, hepatic, renal, and cardiovascular function. Radiation to &gt;/=25% of bone marrow within 14 days of GSK1363089, more than 1 prior anticancer therapy, received prior treatment with a cmet inhibitor, brain metastases, Any uncontrolled intercurrent illness, Pregnant or breastfeeding, HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>c-Met</keyword>
	<keyword>Papillary Renal Cell Carcinoma(PRC)</keyword>
	<keyword>Sporadic papillary renal cell carcinoma,</keyword>
	<keyword>Clear cell renal carcinoma</keyword>
	<keyword>Hereditary papillary renal cell carcinoma,</keyword>
</DOC>